Stowmarket to participate in NHS cancer screening trial
13:59 December 10, 2021
2:26 PM December 10, 2021
Residents of Stowmarket are urged to participate in a trial of a potentially life-saving blood test that could detect more than 50 types of cancer before symptoms appear.
In the coming weeks, townspeople between the ages of 50 and 77 will receive a letter from the NHS urging them to volunteer for the Galleri trial.
Participants, who must not have received a cancer diagnosis or treatment in the past three years, will have blood drawn at a mobile clinic outside the Tesco store in Cedars Link Road between January 17 and February 3 of next year.
They will then be asked to return after 12 months, and again at two years, to give more blood samples.
The test looks for the first signs of cancer in the blood by finding chemical changes in fragments of genetic code that escape tumors into the bloodstream.
The NHS-Galleri trial, the first of its kind, aims to recruit 140,000 volunteers nationwide – including thousands in Stowmarket – to see how well the test works in the NHS.
It is run by Cancer Research UK and King’s College London Cancer Prevention Trials Unit in partnership with NHS England and healthcare company GRAIL, which developed the Galleri test.
Once the mobile clinic collects samples in Stowmarket, it will then move to other locations in the east of England.
Dr Pete Holloway, general practitioner in charge of cancer for Suffolk and North East Essex ICS and East of England Cancer Alliances, said: âMost of us are now aware of the benefits of detecting cancer earlier when it comes to cancer. is easier to process.
âBy participating in this trial, the people of Stowmarket will be at the forefront of developing a test that has the potential to save cancer lives in England and around the world.
âSigning up for the trial is easy – just look for the letter that will show you how to make an appointment online or over the phone. “
Sir Harpal Kumar, President of GRAIL Europe, said: âThe Galleri test can not only detect a wide range of cancer types, but can also predict where the cancer is in the body with a high degree of accuracy. The test is particularly effective at detecting fatal cancers and has a very low false positive rate. “